

OUR PIPELINE

Takeda Oncology is working to discover and develop innovative new therapies that will make a difference in patients' lives.

The molecules in our development pipeline are ordered by their phase in the clinical development process, and within each phase molecules are ordered alphabetically. Phase 1 trials are conducted to determine proper dosing, while Phase 2 and 3 Studies determine the efficacy, side effects and safety of the therapies being researched.

Certain molecules may be under study for more than one disease area. Click on the arrows to learn more about each one.

PROGRAM	PHASE 1	PHASE 2	PHASE 3
BRENTUXIMAB VEDOTIN¹			
DESCRIPTION CD30 Antibody Drug Conjugate	DISEASE(S) UNDER INVESTIGATION Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma		
BRIGATINIB			
DESCRIPTION ALK Inhibitor	DISEASE(S) UNDER INVESTIGATION Non-small Cell Lung Cancer		
IXAZOMIB			
DESCRIPTION Proteasome Inhibitor	DISEASE(S) UNDER INVESTIGATION Multiple Myeloma, Amyloidosis		

PROGRAM	PHASE 1	PHASE 2	PHASE 3
---------	---------	---------	---------

PEVONEDISTAT



DESCRIPTION
Nedd8-Activating Enzyme Inhibitor

DISEASE(S) UNDER INVESTIGATION
High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia

PEVONEDISTAT



DESCRIPTION
Nedd8-Activating Enzyme Inhibitor

DISEASE(S) UNDER INVESTIGATION
Solid Tumors

PONATINIB²



DESCRIPTION
BCR-ABL Inhibitor

DISEASE(S) UNDER INVESTIGATION
Chronic Myeloid Leukemia

PONATINIB²



DESCRIPTION
BCR-ABL Inhibitor

DISEASE(S) UNDER INVESTIGATION
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

PROGRAM

PHASE 1

PHASE 2

PHASE 3

SAPANISERTIB (TAK-228)



DESCRIPTION

TORC1/TORC2 Inhibitor

DISEASE(S) UNDER INVESTIGATION

Endometrial Cancer

SAPANISERTIB (TAK-228)



DESCRIPTION

TORC1/TORC2 Inhibitor

DISEASE(S) UNDER INVESTIGATION

Solid Tumors

TAK-659



DESCRIPTION

SYK/FLT-3 Inhibitor

DISEASE(S) UNDER INVESTIGATION

Lymphoma, Acute Myelogenous Leukemia

TAK-659



DESCRIPTION

SYK/FLT-3 Inhibitor

DISEASE(S) UNDER INVESTIGATION

Solid Tumors

PROGRAM

PHASE 1

PHASE 2

PHASE 3

TAK-931



DESCRIPTION

CDC7 Inhibitor

DISEASE(S) UNDER INVESTIGATION

Pancreatic Cancer, Colorectal Cancer

TAK-931



DESCRIPTION

CDC7 Inhibitor

DISEASE(S) UNDER INVESTIGATION

Solid Tumors

CABOZANTINIB³



DESCRIPTION

MET, VEGF, AXL and RET Inhibitor

DISEASE(S) UNDER INVESTIGATION

Renal Cell Carcinoma

VEDOLIZUMAB



DESCRIPTION

Anti- α 4 β 7 Antibody

DISEASE(S) UNDER INVESTIGATION

Graft versus Host Disease

PROGRAM

PHASE 1

PHASE 2

PHASE 3

NIRAPARIB⁴



DESCRIPTION

PARP Inhibitor

DISEASE(S) UNDER INVESTIGATION

Ovarian Cancer

TAK-522 (XMT-1522)⁵



DESCRIPTION

HER2 Dolaflexin Antibody Drug Conjugate

DISEASE(S) UNDER INVESTIGATION

Breast Cancer

TAK-788 (AP32788)



DESCRIPTION

EGFR/HER2 Inhibitor

DISEASE(S) UNDER INVESTIGATION

Non-small Cell Lung Cancer

TAK-573



DESCRIPTION

CD38-targeted IgG4 fused with attenuated IFN α

DISEASE(S) UNDER INVESTIGATION

Multiple Myeloma

PROGRAM

PHASE 1

PHASE 2

PHASE 3

TAK-164



DESCRIPTION

Anti-guanlyl cyclase C antibody drug conjugate

DISEASE(S) UNDER INVESTIGATION

Pancreatic Cancer, Colorectal Cancer

Last updated 2018-05-10

All programs have Global Development Rights unless otherwise noted.

1 Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. 2 Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories). 3 Japan Only. 4 Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. 5 Ex-U.S., Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc.



ONCOLOGY

©2018 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
All rights reserved. 04/18